Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

Condition(s) studied

Study summary

Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, patients with a PFS \> 6 months could still benefit from them.

The classification of patients with recurrent disease has undergone continuous evolution over time. Essential factors to consider include patient characteristics, disease stage, and the precise genetic and molecular profile of the tumor. This study aims to evaluate survival in patients experiencing recurrence of epithelial ovarian carcinoma with an unfavorable prognosis, with the objective of improving patient categorization and management.

Eligibility

Primary outcome measure(s)

• Characteristic 1 of patients — 2 years
  Weight (Kg) expressed as mean and standard deviation or median and interquartile range, as appropriate.
• Characteristic 2 of patients — 2 years
  Height (cm) expressed as mean and standard deviation or median and interquartile range, as appropriate.
• Characteristic 3 of patients — 2 years
  Age (years) expressed as mean and standard deviation or median and interquartile range, as appropriate.
• Characteristic 4 of patients — 2 years
  ca 125 levels (U/mL) expressed as mean and standard deviation or median and interquartile range, as appropriate.
• Characteristic 5 of patients — 2 years
  Tumor stage (1-2-3-4) expressed as absolute and percentage frequency.
• Characteristic 6 of patients — 2 years
  histotype (HGSOC, LGSOC, HG endometrioid, LG endometrioid, clear cell, other) expressed as absolute and percentage frequency.
• Characteristic 7 of patients — 2 years
  molecular profiling (HRD positive, HRD negative) expressed as absolute and percentage frequency.
• Characteristic 8 of patients — 2 years
  mutation of BRCA ½ (mutation, wild type) expressed as absolute and percentage frequency.

Trial sites (1)

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

Other trials for the same condition